PrecivityAD2™ Blood Test Improves Alzheimer’s Disease Evaluation
Researchers found that C2N Diagnostics‘ PrecivityAD2 blood test improved healthcare providers’ ability to assess the likelihood of Alzheimer’s diseaseAlzheimer’s...
Eli Lilly’s Omvoh gets FDA approval for Crohn’s disease but faces challenges
Eli Lilly’s Omvoh, an IL-23 inhibitor previously approved for ulcerative colitis, has received FDA approval for Crohn’sCrohn’s disease. Despite...
Datopotamab Deruxtecan Recommended for Approval in the EU
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has been recommended for approval...
Cervomed Neflamapimod DLB Program Update at Lewy Body Dementia Conference
CervoMed provided an update on its Phase 2b RewinD-LB trial for neflamapimod in dementia with Lewy bodies (DLB). The...
EU CHMP Positive Opinion for Merck’s Pneumococcal Vaccine in Adults
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Merck’s CAPVAXIVE, a 21-valent...
Regulatory Review Update on Lecanemab for Early Alzheimer’s Disease in the EU
Eisai and Biogen provided an update on the European Union’s regulatory review of lecanemab, a treatment for early-stage Alzheimer’s...
Rapid Medical’s Cognitive Benefit Study on Thrombectomy in Ischemic Stroke
Rapid Medical has enrolled the first patient in its COGNITIVE study, investigating the link between mechanical thrombectomy using their...
DCT Components Improve Trial Access in Underrepresented Communities
New data from the Tufts Center for the Study of Drug Development (CSDD) reveals a correlation between decentralized clinical...
Positive Results in AD04 Study for Alcohol Use Disorder
Adial Pharmaceuticals completed a pharmacokinetic study of AD04, a selective serotonin-3 receptor antagonist for Alcohol Use Disorder (AUD), and...
Lasofoxifene vs. Fulvestrant Effects on Urogenital Symptoms in ER+/HER2- Breast Cancer
Sermonix Pharmaceuticals announced published results from a secondary endpoint analysis of its Phase 2 ELAINE-1 study of lasofoxifene in...